Vetter Receives Internationally Recognized AEO-F Certificate

Vetter has received the status of Authorized Economic Operator Full (AEO-F) from the European Union confirming Vetter reliability, solvency, and high safety standards in international trade. Vetter’s customers worldwide will now benefit from shorter transit times and lower costs with the usual high product quality.

The internationally accepted AEO-F certification (Authorized Economic Operator – Customs simplifications/Security) will facilitate the import of drugs in third countries. The certificate confirms the compliance of high safety requirements throughout the entire supply chain of a company. Customs procedures of consignments will be simplified and accelerated, all of which results in shortened transport durations, as well as improved fulfillment of pharmaceutical requirements for transit times. Another advantage is the facilitation of regulatory proceedings for security reviews and audits. Thus, Vetter and its customers benefit from additional time and cost savings in international supply chains.

“With the recognition afforded by the granting of the AEO-F certificate, we can enable our customers not only a fast and smooth international customs clearance, but more importantly, a very high standard of safety,” said Carsten Press, Senior Vice President Supply Chain Management. “The certification is important for Vetter, and at the same time, it is also further evidence of the high service and product quality we offer to our customers.” With the extended certificate, the benefits of the previous AEO-C status for the European movement of goods also apply at the global level.

The AEO-F certificate is currently accepted by the US and Japan, the EU Member States, Switzerland, Norway and China. The aim of the World Customs Organization is to continue to expand the agreement to additional countries. By expanding the Authorized Economic Operator (AEO) concept, they will establish a uniform customs and security standard in the international movement of goods within the framework of the SAFE (Standards to Secure and Facilitate Global Trade) program. The European Union commends the recognition of the concept in international agreements with third countries in order to protect the supply chain from manufacturers to end users.

Vetter is a premier contract development and manufacturing organization (CDMO) and a global leader in the fill and finish of aseptically prefilled syringe systems, cartridges and vials. Headquartered in Ravensburg, Germany, with facilities in Germany and the United States, the company provides state-of-the-art manufacturing, from early clinical development through commercial filling and packaging of parenteral drugs. The CDMO’s extensive experience covers a broad range of complex compounds, including monoclonal antibodies, peptides and interferons. Vetter supports its customers every step of the way, guiding their products through development, regulatory approval, launch and lifecycle management. Known for quality, the company offers a foundation of experience spanning more than 35 years, including dozens of customer product approvals for novel (bio-)pharmaceutical compounds. In 2014, Vetter began operating a branch in Singapore, and in 2015, a subsidiary in Tokyo, Japan, to increase the presence of the company and the awareness of its service portfolio in the Asian healthcare market. Visit www.vetter-pharma.com.